StreetAlpha.app
Home › Stocks › TECX

Tectonic Therapeutic, Inc. (TECX)

Healthcare
$20.08
▼ −4.29%
LAST CLOSE · NOV 17

Tectonic Therapeutic develops protein and antibody drugs that act on G protein coupled receptors, led by a candidate for pulmonary hypertension. It last closed at $20.08 on Nov 17, down 4.29% on the day. Over the past 90 days StreetAlpha recorded 1 whale options trade in TECX, 100% of them bullish and 0% bearish.

AI Auto Pilots
Is TECX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$88.1M
EPS (diluted)
−$4.63
Free cash flow
−$69.3M
Valuation
Market cap
$400.6M
19.9M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$234.7M
At Sep 30
Shareholder equity
$229.3M
Shares outstanding
19.9M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$119.1M−$119.1MFY2021FY2022: −$105.9M−$105.9MFY2022FY2023: −$42.8M−$42.8MFY2023FY2024: −$58.0M−$58.0MFY2024FY2025: −$74.2M−$74.2MFY2025

From TECX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Hold
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Hold
1firm
0 Buy1 Hold0 Sell
Only 1 firm rated TECX in the past 90 days, not enough for a consensus
Average 12-month target
$26.00
▲ 29.5% upside

Based on 1 analyst who set a price target on TECX in the past 90 days. The average target is $26.00, with a high of $26.00 and a low of $26.00, compared with the last close of $20.08.

Low $26.00Avg $26.00High $26.00
Blue marker: last close $20.08
Highest target$26.00
Average target$26.00
Lowest target$26.00
Latest rating changes
UBSInitiated
Oct 12Hold$26
Wells FargoMaintained
Aug 7Buy$93
Raymond JamesUpgrade
May 26Buy$76 → $81
StifelInitiated
Apr 14Buy$75
Raymond JamesReinstated
Jun 11Buy$76
DateFirmActionRatingPrice target
Oct 12UBSInitiatedHold$26
Aug 7Wells FargoMaintainedBuy$93
May 26Raymond JamesUpgradeBuy$76 → $81
Apr 14StifelInitiatedBuy$75
Jun 11Raymond JamesReinstatedBuy$76
Loading…

Technical Analysis

TECX · as of the Nov 17 close · updated after every close
Downtrend

The stock is 2% below its 20 day and 14% below its 50 day average. It is 40% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 41). The nearest support is the Pivot S1 at $19.54, and the nearest resistance the Pivot at $20.39.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.4%/day
Key levels
$39.5352 week high+96.9%
$28.13200 day average+40.1%
$27.93100 day average+39.1%
$22.9050 day average+14.0%
$21.44Swing high (Oct 29)+6.8%
$20.93Pivot R1+4.2%
$20.5720 day average+2.4%
$20.39Pivot+1.5%
$20.08Last close
$19.54Pivot S1−2.7%
$18.54Swing low (Nov 2)−7.7%
$16.7752 week low−16.5%
Indicators
RSI (14)40.94Middle of its rangeNeutral
MACD-0.54Above its signal lineBullish
Stochastic52.0Middle of its rangeNeutral
ADX (14)30.8Trending down
Williams %R-63.5Oversold below −80, overbought above −20Neutral
CCI (20)-20.9Oversold below −100, overbought above 100Neutral
Rate of change+5.8%Change over 10 sessionsBullish
ATR (14)$1.28Typical daily range, 6.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TECX

What happened before

See how TECX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow TECX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TECX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Sep 1 – Sep 1
Loading…

See today’s whale options flow across the market →

TECX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲60 buying vs 49 selling
  • ▲Held by funds +1.6 pts
  • ▼Funds holding -7
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding116123−5.7%
In funds' top 10110.0%
Held by funds71.6%70.0%+1.6 pts
New / increased13 / 4725 / 39−6.3%
Reduced / sold out29 / 2040 / 11−3.9%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TECX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TECX is in one of them and how their past TECX trades turned out.

TECX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TECX in an article yet. Here's the latest on the wider market.

About Tectonic Therapeutic

Tectonic Therapeutic is a biotechnology company based in Watertown, Massachusetts. It develops therapeutic proteins and antibodies that act on G protein coupled receptors, a family of cell surface molecules that help control many body functions. Its lead candidate, TX45, is a relaxin based molecule being tested for pulmonary hypertension linked to heart and lung disease. The company's work is aimed at patients with serious conditions where treatment options are limited.

Headquarters
Watertown, MA